基本信息
浏览量:427
职业迁徙
个人简介
Johan Neyts is full professor of virology at the University of Leuven, Belgium. His research is focused on the development of novel antiviral strategies against a number of viruses including picornaviruses, flaviviruses and HCV. His laboratory has also a long standing expertise with respect to the development of small animal models for flavivirus infections and with the molecular virology of flaviviruses. His team discovered together with Debiopharm (Lausanne) the anti-HCV activity of Debio-025, a compound which is now in clinical development by Novartis. Together with Prof. Gerhard Puerstinger (University of Innsbruck, Austria) he discovered a novel class of HCV inhibitors, of which the potent compound GS 9190 is now in phase II clinical development at Gilead Sciences (Foster City, CA, USA) under a license agreement with the University of Leuven. He is inventor on a number of patents in the antiviral field.
His work has been published in several book chapters and in more than 200 papers in international scientific journals. He is on the editorial board of the journals ‘Antiviral Research’ and ‘Antiviral Chemistry and Chemotherapy’, ad hoc reviewer for about 30 scientific journals, member of several national and international scientific committees and on the board of directors of the International Society for Antiviral Research. He is the Chief Scientific Officer and co-founder of the spin-out company Okapi Sciences NV. Over the last couple of years he has given about 85 invited lectures. He teaches medical virology at the school of dentistry and the school of medicine at the University of Leuven. He has been honoured with a number of awards including from the Royal Belgian Academy of Medicine, the Belgian Fund for Scientific Research and the International Society for Antiviral Research.
The Neyts lab is/was partner in four large EU funded consortia, i.e. a “Network of Excellence”, VIRGIL on antiviral drug resistance, an “Integrated Project” VIZIER on the replication machinery of RNA viruses as targets to inhibit viral replication, a specific targeted project “Dengframe” to identify strategies to control dengue and the “Coordinated Action” RiviGene on highly pathogenic viruses. Johan Neyts is the coordinator of a large NIAID/NIH funded project on poxvirus inhibitors and a large project on dengue drug discovery funded by the Welcome Trust.
研究兴趣
论文共 539 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Letian Song,Shenghua Gao, Bing Ye, Mianling Yang,Yusen Cheng,Dongwei Kang, Fan Yi, Jin-Peng Sun,Luis Menéndez-Arias,Johan Neyts,Xinyong Liu,Peng Zhan
Acta Pharmaceutica Sinica Bno. 1 (2024): 87-109
Victoire Perraud, Bart Vanderhoydonck,Guillaume Bouvier,Guilherme Dias de Melo, Amuri Kilonda,Mohamed Koukni,Dirk Jochmans, Sophie Rogée, Youcef Ben Khalifa,Lauriane Kergoat, Julien Lannoy, Tina Van Buyten,
Antiviral research (2024): 105838-105838
The Lancet Microbeno. 3 (2024): e247-e260
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024): 116010-116010
引用0浏览0WOS引用
0
0
Phytochemistry Letters (2023): 1-7
引用0浏览0引用
0
0
Christophe Van Dijck,Ian Crozier, Koen Vercauteren, Isabel Brosius,Placide Mbala-Kingebeni,Lori Dodd, Emmanuel Bottieau,Olivier Tshiani Mbaya,Veronique Nussenblatt,Johan Neyts,Laurens Liesenborghs
Clinical Microbiology and Infection (2023)
Tatiana M T Rezende, Gabriella Macera,Leo Heyndrickx,Johan Michiels, Sandra Coppens,Hendrik Jan Thibaut,Kai Dallmeier, Marjan Van Esbroeck,Johan Neyts,Kevin K Ariën,Koen Bartholomeeusen
Kalliopi Pervolaraki,Jean-Christophe Vanherck, Charlene Marcadet,Lieven Verhoye, Amse De Meyer,Madina Rasulova,Heyrhyoung Lyoo,Jasmine Paulissen,Hendrik Jan Thibaut,Kristof De Vos,Patrick Chaltin,Johan Neyts,
JOURNAL OF HEPATOLOGY (2023): S1025-S1025
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn